natgillin/translations-raw huggingface dataset:
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially ‘sodium-free'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. zanemarive količine natrija.
What Somatropin Biopartners contains 
Što Somatropin Biopartners sadrži
When adverse reactions occurred, they tended to be transient and severity was generally mild to moderate. 
Kad su nastale nuspojave, pokazale su se prolaznima i po težini su općenito bile blage do umjerene.
What you need to know before you use Somatropin Biopartners 
Što morate znati prije nego počnete primjenjivati Somatropin Biopartners
Collect the following items before you begin: - supplied in the pack - Somatropin Biopartners vial containing active substance - Somatropin Biopartners vial containing 1.5 mL solvent for suspension for injection - not supplied in the pack - one sterile injection syringe with 19 (19G) or wider Gauge needle to withdraw the solvent - one sterile injection syringe with 26 Gauge (26G) needle for the injection 
Prikupite sljedeći pribor prije nego što počnete: - isporučeno u pakiranju - Somatropin Biopartners bočica koja sadrži djelatnu tvar - Somatropin Biopartners bočica koja sadrži 1,5 ml otapala za suspenziju za injekciju - nije isporučeno u pakiranju - jedna sterilna štrcaljka za injekciju s iglom od 19 Gaugea (19G) ili širom za izvlačenje otapala - jedna sterilna štrcaljka za injekciju s iglom od 26 Gaugea (26G) za injekciju - vatica natopljena alkoholom - suha gaza ili vatica - samoljepivi flaster - kutija za odlaganje uporabljenih štrcaljki i igala
Leukaemia 
Leukemija
A baseline scan is recommended in these patients before instituting growth hormone replacement therapy. 
Preporučuje se početna snimka u ovih bolesnika prije uvođenja nadomjesne terapije hormonom rasta.
Injecting the suspension 
Ubrizgavanje suspenzije
Withdrawing the suspension 
Izvlačenje suspenzije
The solvent is a clear, oily liquid. 
Otapalo je bistra, uljna tekućina.
Excessive glucocorticoid therapy will inhibit the growth-promoting effect of hGH. 
Prekomjerna terapija glukokortikoidima inhibirat će učinak hGH na poticanje rasta.
Remove the needle guard and fill the syringe with a volume of air equal to the required volume of the solvent for injection, making it easier to withdraw the solvent: 
Uklonite štitnik za iglu i napunite štrcaljku volumenom zraka koji je jednak potrebnom volumenu otapala za injekciju, što će olakšati izvlačenje otapala:
Other medicines and Somatropin Biopartners 
Drugi lijekovi i Somatropin Biopartners
Tap and shake the vial of powder to make sure the powder is moving freely. 
Kucnite po bočici s praškom i protresite je kako biste provjerili da se prašak slobodno miče.
Caution should be exercised when this medicinal product is administered to breast-feeding women. 
Potreban je oprez kad se ovaj lijek primjenjuje dojiljama.
Patients receiving concomitant glucocorticoid therapy should have their dose carefully adjusted. 
Bolesnicima koji istovremeno primaju terapiju glukokortikoidima moraju se pažljivo prilagoditi doze.
Solvent: Medium chain triglycerides. 
Otapalo: trigliceridi srednje duljine lanca.
Somatropin therapy has a beneficial effect on body composition in patients with -GHD, in that body fat stores are reduced and lean body mass is increased. 
Terapija somatropinom ima povoljan učinak na sastav tijela u bolesnika s NHR, na način da se smanjuju tjelesne zalihe masti, a povećava bezmasna tjelesna masa.
• Somatropin treatment must not be started in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure or similar conditions. 
• Liječenje Somatropinom ne smije se započeti u bolesnika s akutnom kritičnom bolešću zbog komplikacija nakon otvorene operacije srca ili abodimena, višestrukih traumatskih ozljeda ili u bolesnika s akutnim respiratornim zatajenjem ili slična stanja.
Common: Adrenal insufficiency, decreased free thyroxine, decreased free tri-iodothyronine, increased blood TSH, hypothyroidism* 
Često: adrenalna insuficijencija, smanjeni slobodni tiroksin, smanjeni slobodni trijodotironin, povišeni TSH u krvi, hipotireoidizam*
The frequency of adverse reactions listed below is defined using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data): 
Učestalost niže navedenih nuspojava definirana je pomoću sljedeće konvencije: Vrlo često (≥1/10); često (≥1/100 i <1/10); rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Side effects were generally transient and mild to moderate. 
Nuspojave su općenito bile prolazne i blage do umjerene.
Somatropin Biopartners is indicated for the replacement therapy of endogenous growth hormone in adults with childhood- or adult-onset growth hormone deficiency (GHD). 
Somatropin Biopartners je indiciran za nadomjesnu terapiju endogenim hormonom rasta u odraslih s nedostatkom hormona rasta (NHR) koji je nastao u djetinjstvu ili odrasloj dobi.
Preparing the suspension 
Priprema suspenzije
Holding the needle against the inside vial wall, the entire contents of the syringe should be injected into the powder vial. 
Držeći iglu uz unutarnju stijenku bočice, potrebno je ubrizgati cijeli sadržaj štrcaljke u bočicu s praškom.
Somatropin Biopartners has given rise to the formation of antibodies in approximately 4% of adult patients. 
Somatropin Biopartners izazvao je stvaranje protutijela u približno 4% odraslih bolesnika.
Common: Conjunctivitis, visual acuity reduced 
Često: konjunktivitis, smanjena oštrina vida
- 0.7 mL in a 1 mL graduated syringe for Somatropin Biopartners 10 mg - 1.2 mL in a 2 mL graduated syringe for Somatropin Biopartners 20 mg 
- 0,7 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 10 mg - 1,2 ml u graduiranoj štrcaljki od 2 ml za Somatropin Biopartners 20 mg
Somatropin promotes cellular protein synthesis and nitrogen retention. 
Somatropin potiče sintezu staničnih proteina i zadržavanje dušika.
Somatropin Biopartners is not recommended in women of childbearing potential not using contraception. 
Ne preporučuje se koristiti Somatropin Biopartners u žena reproduktivne dobi koje ne koriste kontracepciju.
Thyroid function should therefore be closely monitored in all patients. 
Stoga se u svih bolesnika mora pažljivo pratiti funkcija štitne žlijezde.
Paediatric population (below 2 years of age) Somatropin Biopartners should not be used in infants below the age of 2 years. 
Somatropin Biopartners ne smije se primjenjivati u dojenčadi mlađe od 2 godine.
Somatropin Biopartners has given rise to the formation of antibodies in approximately 33% of the paediatric patients. 
Somatropin Biopartners doveo je do razvoja protutijela u približno 33% pedijatrijskih bolesnika.
The frequency of adverse reactions listed below is defined using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000), not known (cannot be estimated from the available data): 
Učesatlost niže navedenih nuspojava definirana je pomoću sljedeće konvencije: Vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The maximum retrievable amount of somatropin in one vial of suspension is 20 mg which is sufficient for administration in children of up to 40 kg bodyweight. 
Maksimalna količina somatropina koja se može izvući iz jedne bočice suspenzije je 20 mg, što je dovoljno za primjenu u djece tjelesne težine do 40 kg.
Fatty tissue under the skin can shrink at the site of injection on repeated administration at the same site. 
Potkožno masno tkivo može se stisnuti na mjestu primjene injekcije kad se ponavlja primjena na isto mjesto.
General disorders and administration site conditions Very common: injection site swelling (30.8%) 
Vrlo često: otok na mjestu injekcije (30,8%)
Only stop swirling the vial once the suspension appears uniform, white and all the powder on the bottom is dispersed. 
S mućkanjem kružnim pokretima treba prestati kad suspenzija izgledom postane jednolična, bijela i sav prašak s dna bude raspršen.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 
10. POSEBNE MJERE ZA ZBRINJAVANJE NEISKORIŠTENOG LIJEKA ILI OTPADNIH MATERIJALA KOJI POTJEČU
4 vials of 20 mg powder 
4 bočice s 20 mg praška
- 0.4 mL in a 1 mL graduated syringe for Somatropin Biopartners 2 mg - 0.6 mL in a 1 mL graduated syringe for Somatropin Biopartners 4 mg - 0.9 mL in a 1 mL graduated syringe for Somatropin Biopartners 7 mg 
- 0,4 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 2 mg - 0,6 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 4 mg - 0,9 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 7 mg
Turn the vial upside down, with the syringe in and place the tip of the needle in the suspension as shown in figure 9. 
Okrenite bočicu s uvedenom štrcaljkom naopako i postavite vršak igle u suspenziju kako je prikazano na slici 9.
Long term carcinogenicity studies with Somatropin Biopartners have not been conducted. 
Nisu provedena dugotrajna ispitivanja kancerogenosti Somatropina Biopartners.
Important information about some of the ingredients of Somatropin Biopartners 
Važne informacije o nekim sastojcima Somatropina Biopartners
Uncommon, may affect up to 1 in 100 people - enlargement of the male breast 
Manje često, mogu se javiti u do 1 na 100 osoba - povećanje dojki kod muškaraca
The following adverse reactions have been observed under treatment with Somatropin Biopartners in a 6-month controlled clinical study with 151 adult patients with GHD of adult or childhood-onset and in a 6-month extension study. 
Opažene su sljedeće nuspojave tijekom liječenja Somatropinom Biopartners u 6-mjesečnom kontroliranom kliničkom ispitivanju u 151 odraslih bolesnika s NHR nastalim u odrasloj dobi ili djetinjstvu i u 6-mjesečnom produžetku ispitivanja.
Insert the needle straight through the centre of the vial's rubber stopper into the suspension. 
Uvedite iglu ravno kroz sredinu gumenog čepa na bočici u suspenziju.
These patients should be counselled on risks before initiating therapy. 
Prije početka terapije ovi bolesnici moraju biti obaviješteni o rizicima.
Dosage reductions may be necessary: - in patients above 60 years of age - in patients who develop long lasting tissue swelling caused by fluid retention or who develop abnormal sensations such as prickling, tingling and itchiness - to avoid the development of carpal tunnel syndrome, where the nerve running through the wrist 
Sniženje doze može biti potrebno: - u bolesnika starijih od 60 godina - u bolesnika koji razviju dugotrajni otok tkiva prouzročen zadržavanjem tekućine ili koji razviju abnormalne senzacije kao što su bockanje, trnci i svrbež - da bi se izbjegao razvoj sindroma karpalnog kanala, gdje dolazi do pritiska na živac koji prolazi kroz zapešće (živac medijanus), što dovodi do utrnulosti i bola u šaci - nakon primjene lijeka tijekom produljenog vremenskog razdoblja, osobito u muškaraca.
Common: Impaired fasting glucose, hyperlipidaemia, increased blood insulin, increased blood cholesterol, decreased blood sodium, increased blood triglycerides, increased blood glucose, increased or decreased HDL, increased LDL 
Često: oštećenje tolerancije glukoze natašte, hiperlipidemija, povišen inzulin u krvi, povišen kolesterol u krvi, sniženi natrij u krvi, povišeni trigliceridi u krvi, povišena glukoza u krvi, povišen ili snižen HDL, povišen LDL
Common: Decreased or increased white blood cell count, increased glycosylated haemoglobin, decreased haemoglobin 
Često: smanjeni ili povećani broj bijelih krvnih stanica, povećani glikozilirani hemoglobin, sniženi hemoglobin
Somatropin Biopartners is not recommended during pregnancy. 
Ne preporučuje se koristiti Somatropin Biopartners tijekom trudnoće.
Clean the injection site with an unused alcohol swab. 
Očistite mjesto za injekciju pomoću nove vatice natopljene alkoholom.
IGF-I SDS in the range of +1 to +2 
IGF-I SDS u rasponu od +1 do +2
Somatropin Biopartners is indicated in children and adolescents aged 2 to 18 years for long-term treatment of growth failure due to insufficient secretion of endogenous growth hormone. 
Somatropin Biopartners je indiciran u djece i adolescenata u dobi od 2 do 18 godina za dugotrajno liječenje zastoja u rastu zbog nedovoljnog izlučivanja endogenog hormona rasta.
The following adverse reactions have been observed under treatment with Somatropin Biopartners in a 12-month controlled comparative clinical study in 178 treatment naïve children with growth failure due to insufficient secretion of endogenous growth hormone and in a dose finding study. 
Opažene su sljedeće nuspojave tijekom liječenja Somatropinom Biopartners u 12-mjesečnom kontroliranom usporednom kliničkom ispitivanju u 178 djece koja prethodno nisu bila liječena i imaju zastoj u rastu zbog nedostatnog lučenja endogenog hormona rasta i u ispitivanju pronalaženja doze.
After reconstitution the medicinal product should be used immediately before the suspension settles. 
Nakon rekonstitucije, lijek treba primijeniti odmah prije nego što se suspenzija slegne.
Adults with childhood-onset of GHD 
Odrasli s NHR nastalim u djetinjstvu
After reconstitution the injection should be administered immediately. 
Nakon rekonstitucije, injekcija se mora treba odmah primijeniti.
General disorders and administration site conditions Very common: Oedema peripheral, oedema (local and generalised)* Common: Fatigue, pain, asthenia, face oedema, local swelling, oedema, thirst, malaise, chest pain, increased weight, injection site pain 
Vrlo često: periferni edemi, edemi (lokalni i generalizirani)* Često: umor, bol, astenija, edem lica, lokalni otok, edemi, žeđ, malaksalost, bol u prsištu, povećana tjelesna težina, bol na mjestu injekcije
In patients with an already manifest diabetes mellitus, the anti-diabetic therapy might require adjustment when somatropin treatment is initiated. 
U bolesnika s već manifestnom šećernom bolešću moguća je prilagodba antidijabetičke terapije prilikom započinjanja terapije somatropinom.
Following repeated weekly subcutaneous administration of a mean dose of 4.4 mg prolonged release somatropin to adults with GHD the Cmax and tmax of plasma hGH were about 4.5 ng/mL and 15 h respectively. 
Nakon ponovljene tjedne supkutane primjene srednje doze od 4,4 mg somatropina s produljenim oslobađanjem odraslima s NHR, Cmax ljudskog hormona rasta (hGH) u plazmi iznosio je oko 4,5 ng/ml, a tmax oko 15 sati.
Powder and solvent for prolonged-release suspension for injection 20 mg powder in a vial and 1.5 mL solvent in a vial 1 vial of 20 mg powder 
Prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem 20 mg praška u bočici i 1,5 ml otapala u bočici 1 bočica s 20 mg praška
Information about self-injection of Somatropin Biopartners 
Informacije o samoubrizgavanju Somatropina Biopartners
Apply gentle pressure to the injection site with a dry gauze or cotton pad. 
Lagano pritisnite mjesto injekcije suhom gazom ili vaticom.
4 vials of 10 mg powder 
4 bočice s 10 mg praška
For the treatment of children and adolescents aged 2 to 18 years the 10 mg and 20 mg vials of this medicinal product should be used. 
Za liječenje djece i adolescenata u dobi od 2 do 18 godina moraju se koristiti bočice od 10 mg i 20 mg ovog lijeka.
Common: Nausea 
Često: mučnina
Very common: Mild hyperglycaemia* 
Vrlo često: blaga hiperglikemija*
In children, Somatropin Biopartners should be administered subcutaneously at a concentration of 20 mg/mL. 
U djece se Somatropin Biopartners mora primijeniti potkožno u koncentraciji od 20 mg/ml.
Apply gentle pressure to the plunger to get rid of the bubbles. 
Primijenite lagani pritisak na klip kako biste uklonili mjehuriće.
The plunger should be pushed up gently, until all bubbles are removed from the syringe and needle. 
Klip treba nježno potiskiati sve dok se ne uklone svi mjehurići iz štrcaljke i igle.
*produced in Saccharomyces cerevisiae by recombinant DNA technology For the full list of excipients, see section 6.1. 
*proizvedeno u kvascu Saccharomyces cerevisiae pomoću tehnologije rekombinantne DNK
After preparation, the product must be used immediately. 
Nakon pripreme, lijek se mora odmah primijeniti.
Following repeated weekly subcutaneous administration of a mean dose of 0.5 mg/kg prolonged release somatropin to prepubertal children with GHD the Cmax and tmax of plasma hGH were about 60.7 ng/mL and 12.0 h respectively. 
Nakon ponovljene tjedne supkutane primjene srednje doze od 0,5 mg/kg somatropina s produljenim oslobađanjem predpubertskoj djeci s NRH, Cmax hGH u plazmi iznosio je oko 60,7 ng/ml, a tmax oko 12,0 sati.
Common, may affect up to 1 in 10 people - virus infection known as Herpes simplex - skin tag (a form of harmless skin growth) - tiredness - weakness, feeling unwell - face swelling - thirst - pain, chest pain, pain at the injection site - pain in the back, arms, legs, shoulders, bones, joints - sleeplessness - decreased sensation, numbness and tingling in fingers and palm of the hand due to squeezed nerve at wrist (carpal tunnel syndrome) - dizziness, sleepiness - muscular or bone stiffness, weakness of the muscles, muscle pain, feeling of heaviness - inflammation of the tendons, joint swelling, joint inflammation - reddening of the eyes, reduced vision, vertigo (a feeling of dizziness or spinning) - increased or irregular heart rate - high blood pressure - nosebleed - nausea - increased level of bilirubin, a substance produced by the liver - inflammation of the gall bladder - acne, increased sweating, skin rash - allergic skin reactions such as redness, irritation, itching - blood in the urine - nipple pain - reduced function of the adrenal gland (which could show as tiredness) - reduced function of the thyroid gland - increased fat levels in the blood - weight gain - development of substances (antibodies) in the blood that bind to growth hormone - changes in blood test results such as a change in the number of white blood cells or increased levels of insulin, sugar, sodium or certain fatty substances in the blood - changes in liver test results - a type of benign brain tumour called craniopharyngioma 
Često, mogu se javiti u do 1 na 10 osoba - infekcija virusom koji se zove Herpes simplex - kožni fibromi (oblik bezopasne izrasline na koži) - umor - slabost, loše osjećanje - otok lica - žeđ - bol, bol u prsištu, bol na mjestu injekcije - bol u leđima, rukama, nogama, ramenima, kostima, zglobovima - nesanica - smanjen osjet, utrnulost i trnci u prstima i dlanovima zbog pritisnutog živca u zapešću (sindrom karpalnog kanala) - omaglica, pospanost - mišićna ili koštana ukočenost, slabost mišića, mišićni bol, osjećaj težine - upala tetiva, otok zglobova, upala zglobova - crvenilo očiju, oslabljen vid, vrtoglavica (osjećaj omaglice ili vrtnje) - ubrzan ili nepravilan rad srca - povišen krvni tlak - krvarenje iz nosa - mučnina - povišena razina bilirubina, tvari koju proizvodi jetra - upala žučnog mjehura - akne, pojačano znojenje, kožni osip - alergijska kožna reakcija, kao što je crvenilo, nadraženost, svrbež - krv u mokraći - bol u bradavicama - smanjena funkcija nadbubrežne žlijezde (koja se može očitovati kao umor) - smanjena funkcija štitne žlijezde - povišene razine masnoća u krvi - povećanje tjelesne težine - razvoj tvari (protutijela) u krvi koje se vežu na hormon rasta - promjene u rezultatima krvnih pretraga kao što je promjena broja bijelih krvnih stanica ili povišene razine inzulina, šećera, natrija ili određenih masnih tvari u krvi - promjene u rezultatima jetrenih pretraga - vrsta dobroćudnog tumora mozga koji se zove kraniofaringeom
Somatropin Biopartners 10 mg is sufficient for use in children up to 20 kg bodyweight. 
Somatropin Biopartners 10 mg dovoljan je za primjenu u djece tjelesne težine do 20 kg.
For the treatment of children and adolescents aged 2 to 18 years vials with 10 mg and 20 mg somatropin should be used. 
Za liječenje djece i adolescenata u dobi od 2 do 18 godina moraju se koristiti bočice s 10 mg i 20 mg somatropina.
Apply gentle pressure by pushing the plunger up, until all bubbles are removed from the syringe and needle. 
Nježnim pritiskom potisnite klip prema gore, sve dok svi mjehurići ne budu uklonjeni iz štrcaljke i igle.
Contact your doctor if this happens. 
Ako se to dogodi, obratite se liječniku.
Somatropin Biopartners 20 mg is sufficient for use in children up to 40 kg bodyweight. 
Somatropin Biopartners 20 mg dovoljan je za primjenu u djece tjelesne težine do 40 kg.
Psychiatric disorders Very rare: insomnia* 
Vrlo rijetko: nesanica*
The syringe should be filled with the correct volume of the solvent for injection as listed above and the syringe needle withdrawn from the vial subsequently. 
Štrcaljku treba napuniti ispravnim volumenom otapala za injekciju kako je navedeno gore i iglu štrcaljke nakon toga izvući iz bočice.
Uncommon: Gynaecomastia* 
Vrlo rijetko: ginekomastija*
Common, may affect up to 1 in 10 people - tiredness or weight gain due to underactive thyroid gland - reduced function of the adrenal gland (which may show as tiredness) - mild blood sugar increase - headache, lethargy (lack of energy), dizziness - vomiting, stomach ache - discoloration of the skin - pain in joints, arms or legs - pain, discoloration, swelling, hardening, reddening or feeling of warmth at the injection site - tissue swelling - fever - changes in blood levels of certain hormones 
Često, mogu se javiti u do 1 na 10 osoba - umor ili povećanje tjelesne težine zbog smanjene aktivnosti štitne žlijezde - smanjena funkcija nadbubrežne žlijezde (što se može očitovati kao umor) - blago povišen šećer u krvi - glavobolja, letarija (nedostatak energije), omaglica - povraćanje, bol u želucu - promjena boje kože - bol u zglobovima, rukama ili nogama - bol, promjena boje, otok, otvrdnuće, crvenilo ili žarenje na mjestu injekcije - otok tkiva - vrućica - promjene razine određenih hormona u krvi
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2).
No clinical studies have been conducted with Somatropin Biopartners in breast-feeding women. 
Nisu provedena klinička ispitivanja Somatropin Biopartnersa u dojilja.
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ(I) BIOLOŠKE(IH) DJELATNE(IH) TVARI I PROIZVOĐAČ(I) ODGOVORAN(ODGOVORNI)ZA PUŠTANJE SERIJE LIJEKA U PROMET
The other ingredients are sodium hyaluronate, egg phospholipids, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. 
Drugi sastojci su natrijev hijaluronat, fosfolipidi jaja, natrijev dihidrogenfosfat bezvodni i natrijev hidrogenfosfat bezvodni.
Somatropin Biopartners 2 mg powder and solvent for prolonged-release suspension for injection Somatropin Biopartners 4 mg powder and solvent for prolonged-release suspension for injection Somatropin Biopartners 7 mg powder and solvent for prolonged-release suspension for injection 
Somatropin Biopartners 2 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Somatropin Biopartners 4 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Somatropin Biopartners 7 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Do not use Somatropin Biopartners 
Nemojte primjenjivati Somatropin Biopartners
1 vial of 1.5 mL solvent 
1 bočica s 1,5 ml otapala
For storage conditions of the reconstituted medicinal product, see section 6.3. 
Uvjete čuvanja nakon rekonstitucije lijeka vidjeti u dijelu 6.3.
Metabolism and nutrition disorders Common: Mild hyperglycaemia* Not known: Insulin resistance* 
Često: blaga hiperglikemija* Nepoznato: inzulinska rezistencija*